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Simple Summary: Antimicrobial resistance (AMR) is a major threat to public health. There are
concerns that antimicrobial use (AMU) in agriculture has a role in the development of AMR. Pigs are
one of the main consumers of veterinary antimicrobials and a better understanding of the drivers for
AMU in this sector will help in efforts to reduce use. The aim of this study was to investigate the
associations between antimicrobial use, farm characteristics, biosecurity, the presence of respiratory
disease on the farm and health management practices on Irish pig farms. Farms that manufactured
their feed on-site had lower total AMU than farms that purchased their feed from a feed mill. Higher
levels of lung abscesses and pericarditis (inflammation of the lining around the heart), both indicators
of respiratory disease, were associated with increased AMU. Higher levels of pericarditis were also
associated with increased use of critically important antimicrobials. Farms vaccinating against swine
influenza also had higher AMU. Farms that administered prophylactic antimicrobial treatments to
piglets had higher use of individual treatments and critically important antimicrobials. The results
from this study show that prophylaxis and respiratory disease are the main drivers of AMU on
Irish pig farms. These findings highlight areas of farm management where interventions may aid in
reducing AMU on Irish pig farms.
Abstract: The threat to public health posed by antimicrobial resistance in livestock production means
that the pig sector is a particular focus for efforts to reduce antimicrobial use (AMU). This study
sought to investigate the risk factors for AMU in Irish pig production. Antimicrobial use data were
collected from 52 farrow-to-finish farms. The risk factors investigated were farm characteristics
and performance, biosecurity practices, prevalence of pluck lesions at slaughter and serological
status for four common respiratory pathogens and vaccination and prophylactic AMU practices.
Linear regression models were used for quantitative AMU analysis and risk factors for specific AMU
practices were investigated using logistic regression. Farms that milled their own feed had lower total
AMU (p < 0.001), whereas higher finisher mortality (p = 0.043) and vaccinating for swine influenza
(p < 0.001) increased AMU. Farms with higher prevalence of pericarditis (p = 0.037) and lung abscesses
(p = 0.046) used more group treatments. Farms with higher prevalence of liver milk spot lesions
(p = 0.018) and farms practising prophylactic AMU in piglets (p = 0.03) had higher numbers of
individual treatments. Farms practising prophylactic AMU in piglets (p = 0.002) or sows (p = 0.062)
had higher use of cephalosporins and fluoroquinolones. This study identified prophylactic use and
respiratory disease as the main drivers for AMU in Irish pig production. These findings highlight
areas of farm management where interventions may aid in reducing AMU on Irish pig farms.
Keywords: antimicrobial use; biosecurity; Ireland; pigs; respiratory disease; risk factors
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1. Introduction
Antimicrobial resistance (AMR) is a continued and increasing threat to global public
health [1]. Improved antimicrobial stewardship and ultimately reduced antimicrobial use
(AMU) are key components of various action plans to mitigate this threat [2,3]. Antimi-
crobial use in livestock production is a focus of concern because it accounts for a large
proportion of global AMU [4] and animals may act as a reservoir for AMR pathogens and
AMR genes [5]. Furthermore, the literature suggests that restricting AMU in livestock can
reduce AMR in animals and humans [6].
The pig sector is a major consumer of veterinary antimicrobials (AMs) and ranks
highest in several countries [7–9]. In pig production, AMs are primarily administered as
group treatments to piglets post-weaning, via oral routes of administration and more often
at strategic times in the production cycle [10,11]. A better understanding of the risk factors
for this AMU will aid in efforts to reduce it. Antimicrobials are used for the treatment,
prevention and control of infectious disease [12–14], and respiratory and gastrointestinal
disease are the major indications for use [11,15,16]. Therefore, it would be expected that
disease burden is the primary driver for AMU. However, the relationship between disease
burden and AMU is not well-characterised [17,18].
Farm characteristics and management practices such as herd size [19–21], proximity to
other pig farms [20,22,23], raising finisher pigs on specialised farms (which may use multi-
ple suppliers) [20,21], increased farrowing rhythm and longer suckling period [24] can also
influence AMU. Furthermore, higher levels of biosecurity [24,25] and implementing some
specific biosecurity practices, such as provision of changing facilities [26] and provision of
boots to visitors [22], are also associated with reduced AMU. Vaccination is considered a
key tool in disease control and in reducing reliance on AMU [27–30]. However, despite
effectiveness in field studies [31–33], vaccination has been associated with increased AMU
in several studies [17,24,30,34,35]. Finally, socio-economic and demographic factors such as
age, gender, education or years of experience [36] and attitudes to AMR [37] can influence
on farm AMU, although their relative importance appears to differ depending on nation-
ality [17]. In general, pig farmers perceive AMs as an effective and cost-efficient tool in
disease management [30,38–40] and, at least in the past, were poorly aware or unconcerned
about the risks of AMR [38,39,41].
There is little information about the factors associated with the choice of AM treatment,
i.e., active ingredient and route of administration, on pig farms [42]. The various AMs
have specific indications for use, and many are licensed to treat more than one condition.
There are official national guidelines dictating which AMs should be used for specific
conditions [43,44]. However, they are not always followed [15,45] and there can be notable
variation in choice of treatment for the same condition [46]. A better understanding of the
reasons behind such choices may aid in improving antimicrobial stewardship and would
be especially useful for the highest priority critically important antimicrobials (HP CIA)
which are most important to public health.
According to Collineau et al., the relative importance of risk factors associated with
AMU varies between countries [17]. In Ireland, pig production accounts for approximately
40% of veterinary AM consumption, with prophylactic administration of medicated feed
being the dominant practice [47], but the drivers for this use on Irish farms have not been
studied previously. This study aimed to explore the risk factors for AMU in a cohort of Irish
farrow-to-finish farms using AMU, biosecurity, respiratory disease and farm management
data. A further aim was to investigate risk factors for specific AMU practices, namely the
choice of AM class and route of administration.
2. Materials and Methods
2.1. Farm Selection
This cross-sectional study was conducted on a sample of 52 Irish pig farms to in-
vestigate risk factors for AMU. The risk factors investigated were grouped as follows:
biosecurity practices; farm management practices, including vaccination; farm status and
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prevalence of respiratory disease; and farm performance indicators. The study farms were
part of a larger cohort of farms that participated in two separate but closely related projects,
investigating (1) antimicrobial use and (2) respiratory disease, which were conducted from
February 2016 to September 2018. All participants were clients of the Teagasc (Teagasc, the
Agriculture and Food Development Authority, https://www.teagasc.ie/animals/pigs/
accessed on 20 September 2021) farm advisory service, which is available to all Irish pig
farms. In 2017, the Teagasc farm advisory service included 107 pig farms, representing over
77,000 sows (approximately 50% of the national herd) [48]. All client farms were invited to
participate in both projects on a voluntary basis, and the 52 farms in this study represent
those that provided sufficient data to both the AMU and the respiratory disease projects.
2.2. Farm Production and Performance
The study farms submit their production data to the Teagasc e-Profit Monitor (ePM)
database quarterly. The following indicators for the 2016 calendar year were extracted from
the ePM database: herd size, piglet, weaner and finisher mortality, average age at weaning,
at transfer to finisher and at slaughter (which were used to calculate length of stay in the
weaner and finisher stages), average daily gain (ADG) and feed conversion ratio (FCR).
2.3. Antimicrobial Use
Antimicrobial use data for the 2016 calendar year were collected for each farm by
means of farm visits conducted from September 2017 to September 2018, as previously
described by O’Neill et al. [47]. In short, details of AMU in medicated feed regarding the
diets and age groups treated and the AMs used were provided by the farmers. The amounts
of AMs in oral remedies other than premix (i.e., not for medicated feed) and injectable
preparations were determined using invoice and or prescription records. Feed consumption
data (to calculate amount of medicated feed) and population data were extracted from
the ePM database. Treatment incidence (TI), which represents the percentage of pigs in a
stage of production treated with a dose of AM each day (or equivalently, the percentage
time of the period at risk for which a pig was treated) [49], was calculated for each AM
and route of administration in each stage of production (piglet, weaner and finisher). The
TI was calculated using the formula adapted by Sarrazin et al. [11] and the Defined Daily
Dose (DDDvet) for each AM, as assigned by the European Medicines Agency (EMA) [50],
and standard weights for each age group, as proposed by the European Surveillance of
Veterinary Antimicrobial Consumption (ESVAC) project [51]:
TIDDDvet =
amount of antimicrobial used (mg)
DDDvet (mg/kg)× kg of animal at risk (kg)× number of days at risk
× 100 animals at risk (1)
The TI values for piglets, weaners and finishers were then combined to calculate the
standardised TI200 indicator, which represents AMU for the entire rearing period, using
the formula defined by Sjölund et al. [10]:
TI200 =
TIpiglet × suckling period + TIweaner × weaner period +TIfinisher × fininshing period
total rearing period
×200 (standard life span)
total rearing period
(2)
Information on which vaccinations were used on the farm and whether the farm
administered prophylactic AM treatments (other than in medicated feed) in the different
production stages (by any route of administration) was also collected for each farm.
2.4. Biosecurity Assessment and Farm Management Practices
Biosecurity practices were assessed using the Biocheck.UGentTM (https://bioche
ck.ugent.be/en accessed on 20 September 2021) questionnaire, which was completed
during the course of farm visits conducted between February and May 2016 [52]. The
Biocheck.UGentTM questionnaire consists of 109 closed questions which assess various
biosecurity measures and farm management practices. Questions on farm characteristics
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do not contribute to the biosecurity score and include the age of the oldest and youngest
buildings, the number of employees and the experience of the farm manager/owner.
Information on whether the farm milled its own feed or purchased from an external
feed mill was also collected. Biosecurity-related questions are grouped into six external
biosecurity categories and six internal biosecurity categories. Each question contributes a
weighted score to its category and each category contributes a weighted score to the external
or internal biosecurity score. The overall biosecurity score is computed as the average of
the external and internal biosecurity scores. Scores range from 0 to 100, where 0 indicates
the absence of biosecurity and 100 represents perfect biosecurity. The questionnaire for
pigs is described in detail by Laanen et al. [25]. The scores for each category as well as the
internal, external and overall biosecurity scores were used in the statistical analysis.
2.5. Respiratory Disease Status and Farm Prevalence
Data on disease status and prevalence of pluck (lungs, heart and liver) lesions were
collected from November 2017 to April 2018, as previously described by Rodrigues da
Costa et al. [53]. Disease status for Influenza A virus (IAv), Porcine reproductive and
respiratory syndrome virus (PRRSv), Mycoplasma hyopneumoniae (Mhyo) and Actinobacillus
pleuropneumoniae (APP) was determined using serological testing. Thirty-two samples per
farm were collected and processed at the Blood Testing Laboratory of the Department of
Food, Agriculture and the Marine (Cork, Ireland). Serum was separated from the samples
and stored at −80 ◦C until further analysis. For analysis, all 32 samples were used for
detection of IAv and PRRSv (allowing for a minimum within-herd prevalence of 10%,
α = 0.05), while 16 samples were used for detection of Mhyo and APP (allowing for a
minimum within-herd prevalence of 18%, α = 0.05). The seroprevalence of antibodies
against IAv, PRRSv, Mhyo and APP were determined using the respective IDEXX ELISA
kits, for the four respiratory pathogens: Influenza A Ab Test, PRRS X3 Ab Test, HerdChek
Mycoplasma hyopneumoniae Ab Test and APP-ApxIV Ab Test (IDEXX, Hoofddorp, The
Netherlands), according to the manufacturer’s instructions. Farms were considered positive
if at least one sample tested positive by the relevant serological test.
All pluck examinations were carried out by a single trained veterinarian. Lungs were
removed from the carcass by abattoir personnel and scored in the evisceration line for
pneumonic lesions using the method described by Madec and Derrien [54]. Pleurisy in
the dorsocaudal lobes was scored using a modified version of the Slaughterhouse Pleurisy
Evaluation System (SPES) [55,56] with a 4-point scale, in which 0 = no pleurisy, 2 = focal
lesions in one lobe, 3 = bilateral adhesions or unilateral lesions affecting more than 1/3
of one diaphragmatic lobe and 4 = extensive lesions affecting more than 1/3 of both
diaphragmatic lobes (SPES score = 1 corresponds to cranial pleurisy and is not used in the
modified SPES scoring system). The prevalence of dorsocaudal pleurisy, i.e., lesions with
SPES score ≥ 2, and the prevalence of moderate or severe dorsocaudal pleurisy, i.e., lesions
with SPES score 3 or 4, were used for statistical analysis. Additionally, scars, indicative of
healing pneumonic lesions from previous infection, cranial pleurisy (adhesions between
lobes, on the surface of the apical and cardiac lobe, and/or adhesions between the lung and
the heart), pericarditis (expansion of the pericardial cavity with inflammatory exudate [57]),
lung abscesses and liver spots (indicative of transhepatic migration of the larvae of Ascaris
suum [58]) were recorded as present or absent.
2.6. Data Processing and Statistical Analysis
All data were entered into a Microsoft® Excel 365 (Microsoft Corporation, Redmond,
WA, USA) spreadsheet. Calculations and statistical analyses were carried out using
Microsoft® Excel and R version 3.4.2 [59]. Data visualisation was carried out using the
ggplot2 and VennDiagram packages in R [60,61]. Two separate analyses were carried out
to investigate risk factors associated with (1) quantitative AMU and (2) AMU practices.
For the quantitative AMU analysis, the outcome variables were total TI200 for group
oral treatments administered (TIgroup), total TI200 for individual treatments (TIindividual),
Animals 2021, 11, 2828 5 of 23
combined TI200 for ceftiofur and fluoroquinolones (TIceflq) and total TI200 for all routes of
administration (TItotal). Variables were checked for normality by examining the quartile-
quartile plot and by using the Shapiro–Wilks test. The four outcome variables were not
normally distributed and thus, a log transformation was applied to approach a normal
distribution. The transformation of TIgroup and TIceflq required the addition of a constant (1
and 0.01, respectively) to account for farms with zero AMU in these categories. Collinearity
among the predictor variables was checked using Spearman rank correlations for contin-
uous variables, Wilcoxon rank sum test for continuous and categorical variables and chi
squared or Fisher’s exact test for categorical variables. Categorical predictor variables (all
were binary in this dataset) with less than 10 farms in either category were excluded from
further analysis. For each outcome variable, the associations with each of the predictor
variables were first assessed using univariable linear regression models. A multivariable
linear regression model was then created using predictor variables with p ≤ 0.25 in the
univariate analysis. Where there was collinearity among the predictor variables (Spearman
rho > 0.7 or p-value of chi-square/Fisher tests ≤ 0.05), the variable with the strongest
association in the univariable model or the one with the most biological significance was
selected. Alpha level for determination of significance was 0.05 and trends are discussed
between 0.05 and 0.1. The model was then refined using manual backward selection,
removing the predictor variable with the highest p-value until all remaining variables had
a p ≤ 0.1.
Associations between specific AMU practices and the predictor variables were inves-
tigated using logistic regression. Here, the outcome variables were each combination of
AM class and the two main routes of administration: oral group treatments (eight outcome
variables) and individual treatments (eight outcome variables). Collinearity among the
predictor variables was checked as per the quantitative AMU analysis and categorical
variables with less than 10 farms in either category were excluded from the analysis. Uni-
variable associations between each outcome variable and predictor variable were assessed
using chi-squared or Fisher’s exact test along with the respective odds ratio if the predic-
tor variable was categorical, and univariable logistic regression for continuous variables.
Thresholds for significance and tendency were set as for the linear regression analysis.
Multivariable logistic regression models were then created using predictor variables with
p ≤ 0.25 in the univariate analysis and refined using manual backward selection until all
remaining variables had a p ≤ 0.1.
3. Results
A summary of the farm characteristics and production data is presented in Table S1.
The 52 farms had a combined population of 38,764 sows and thus represented approx-
imately 29% of the national herd in 2016. The median herd size was 650 sows (range:
113–2354) and all farms operated a farrow-to-finish system which accounts for virtually
all pig production in Ireland [62]. Twenty-two farms (42.3% of sample) practised home
milling, whereby at least one diet was manufactured on the farm, while the remaining
farms purchased all feed. Antimicrobial use expressed as TI200 is summarised in Table 1.
The median TI200 was 14.2 (range: 0.2–169.1). Oral group treatments accounted for 93.3%
of consumption (81.5% via medicated feed, 11.6% via water) and were administered on all
but two farms. Provision of medicated feed to piglets via starter and/or link diets during
the first 7 to 21 days post-weaning was standard practice on 44 farms (84.6% of sample),
and 27 farms (51.9% of sample) provided medicated feed in the subsequent diets (see
O’Neill et al. [47] for a full description). All farms administered individual AM treatments.
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Table 1. Antimicrobial use on 52 Irish farrow-to-finish pig farms during 2016 summarised by mode of treatment. The
number of farms using each antimicrobial class and the mean and median treatment incidence (TI200) for each mode of
treatment is shown.
Antimicrobial Class Farms with Use Mean (SD) Median (Range)
Oral group treatments
Tetracylines 38 (73.1%) 7.7 (12) 1.2 (0–49.1)
Potentiated sulphonamides 17 (32.7%) 6.6 (22.8) 0 (0–150.1)
Penicillins 36 (69.2%) 2.7 (5.5) 0.9 (0–29.7)
Macrolides 23 (44.2%) 2.3 (4.4) 0 (0–23.6)
Lincosamides 10 (19.2%) 0.1 (0.5) 0 (0–2.9)
Amphenicols 7 (13.5%) 0.1 (0.4) 0 (0–2.5)
Aminoglycosides 27 (51.9%) 0.5 (1.3) 0 (0–8.9)
Aminocyclitols * 10 (19.2%) 0.1 (0.3) 0 (0–1.9)
Polymyxins 13 (25%) 0.8 (2.6) 0 (0–13)
Total oral group treatments (TIgroup) 50 (96.2%) 21 (28.5) 13.3 (0–167.8)
Individual treatments
Tetracyclines 22 (42.3%) 0.1 (0.2) 0 (0–0.9)
Potentiated sulphonamides 8 (15.4%) 0.1 (0.3) 0 (0–2.2)
Penicillins 52 (100%) 0.6 (0.6) 0.4 (0–2)
Macrolides 18 (34.6%) 0.2 (0.6) 0 (0–4)
Lincosamides 21 (40.4%) 0 (0) 0 (0–0.2)
Amphenicols 5 (9.6%) 0 (0) 0 (0–0.3)
Aminoglycosides 14 (26.9%) 0 (0.1) 0 (0–0.3)
Aminocyclitols 23 (44.2%) 0 (0) 0 (0–0.2)
Fluoroquinolones 45 (86.5%) 0.2 (0.3) 0.1 (0–1.2)
Cephalosporins 12 (23.1%) 0.2 (0.8) 0 (0–4.6)
Pleuromutilins 1 (1.9%) 0 (0) 0 (0–0)
Total individual treatments (TIindividual) 52 (100%) 1.5 (1.6) 1.1 (0.1–11.4)
Total antimicrobial use (TItotal) 52 (100%) 22.5 (28.6) 14.2 (0.2–169.1)
Cephalopsorin and/or fluoroquinolone use (TIceflq) 47 (90.4%) 0.5 (0.9) 0.2 (0–5.8)
* Aminocyclitols in group treatments were used in combination with lincosamides. Legend: TI—treatment incidence.
The breakdown of AMU by AM class and stage of production is shown in Figure 1. The
most frequently used AM classes overall were tetracyclines, potentiated sulphonamides,
penicillins and macrolides, accounting for 34.8%, 32.5%, 12.9% and 11.5% of AMU, respec-
tively. Fluoroquinolones and cephalosporins accounted for 1.8% of AMU and were used
on 90.4% of farms. Weaner pigs received 80.5% of all doses, but piglets accounted for 65%
of individual treatments. The biosecurity scores for the study farms are summarised in
Table S2. Farms typically had higher scores in external biosecurity (median 79.5 (range:
62–94)) than in internal biosecurity (60 (range: 29–80)). The category with the highest score
was ‘purchase of animals and semen’, where 49 farms (94.2% of sample) had a perfect
score, while the lowest scoring category was ‘cleaning and disinfection’ (median 38 (range:
0–95)). The farm vaccination and AM prophylaxis practices are summarised in Table S3.
All farms administered Erysipelothrix rhusopathiae and parvovirus vaccination to sows.
Vaccination against IAv and PRRSv was carried out on 19 and 21 farms, respectively (of
which 11 vaccinated against both). Piglets were vaccinated against porcine circovirus type
2 (PCV-2) on 94.2% of farms and 75% also vaccinated against Mhyo. Half of all farms
administered prophylactic AM treatments to piglets, typically in the first week of life either
after birth or at processing (teeth clipping, iron injection, tail docking, etc. (castration is not
routine practice in Irish pig production)). Twenty farms (38.5% of sample) administered
prophylactic treatments to sows mainly via medicated feed or injections around farrowing
or weaning. A summary of farm disease status for IAv, PRRSv, Mhyo and APP, and the
prevalence of pluck lesions at slaughter, are shown in Table S4. All but one farm was
positive for APP. Co-infection with other pathogens was common: 80.7% of farms (n = 42)
were positive for at least three of the four pathogens, while 38.4% (n = 20) were positive for
all four (see Figure S1).
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Figure 1. Breakdown of antimicrobial use by antimicrobial class and stage of production for indi-
vidual treatments, cephalosporin and fluoroquinolone treatments, group oral treatments and total
antimicrobial use on 52 Irish farrow-to-finish farms during 2016. Percentage of use refers to the
contribution of the antimicrobial class or stage of production to the overall treatment incidence
(TI200) indicator. Legend: cef + flq—use of cephalosporins and fluoroquinolones.
The univariable linear regression models for the TItotal, TIgroup, TIindividual and TIceflq
are summarised in Table S5. The final multivariable models are shown in Table 2. There
were significant positive associations between all the pleurisy-related variables (p ≤ 0.05)
and both TItotal and TIgroup, but these were not retained in the final models. The final
multivariable models for TItotal and TIgroup were similar and explained approximately 53%
and 55% of the variability, respectively. Farms with higher mortality in the finisher stage
and those vaccinating against IAv had higher AMU, while farms home milling and farms
with longer weaner stages had lower AMU (p ≤ 0.05). There were positive associations
between prevalence of lung abscesses and pericarditis and AMU, although these were not
significant for the TItotal (p ≤ 0.1). The final multivariable model for TIindividual explained
29% of the variability, with the administration of prophylactic AM treatments to piglets,
higher biosecurity score in ‘vermin and bird control’ and prevalence of liver milk spots
being positively associated with individual AMU (p ≤ 0.05). Farms with better biosecurity
scores in ‘feed, water and equipment supply’ had reduced individual AMU (p = 0.007).
Regarding the use of fluoroquinolones and third-generation cephalosporins, the model
for TIceflq explained 37% of the variability. Farms with prophylactic AMU in piglets, those
with lower biosecurity scores in ‘feed and water supply’ and those with higher prevalence
of pericarditis used more of these classes (p ≤ 0.05). Farms with higher weaner mortality
used less (p = 0.002), while farms which administered prophylactic AM treatments to sows
tended to use more (p = 0.062).
The univariable associations between the predictor variables and the use (or not) of
the various combinations of antimicrobial class and route of administration (group or
individual) are shown in Table S6. The results from the final logistic regression models for
AM classes used as group oral treatments are shown in Tables 3 and S7 and are presented
as odds ratios with their 95% confidence intervals. The associations identified in the
quantitative analysis of total and group oral AMU were also identified as risk factors
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for use of the most consumed AM classes. Home milling farms were less likely to use
tetracyclines (p = 0.048) and farms with a longer weaner stage were less likely to use
tetracyclines, potentiated sulphonamides or lincosamides as group treatments (p < 0.05).
Higher finisher mortality was associated with increased odds of potentiated sulphonamide
use (p = 0.033) and macrolide use (p = 0.014). Farms positive for IAv were less likely
to use oral penicillins (p = 0.041), but those vaccinating against IAv were more likely
to use oral tetracyclines, potentiated sulphonamides and macrolides (p < 0.05). Higher
prevalence of pericarditis was associated with increased odds of penicillin use (p = 0.007)
and polymyxin use (p = 0.046). Farms that administered prophylactic AM treatments to
piglets were 10 times more likely to use oral penicillins (p = 0.006). Higher scores in the
biosecurity categories ‘nursery unit management’ and ‘measures between compartments’
were associated with decreased odds of tetracycline use (p = 0.04) and polymyxin use
(p = 0.026), respectively. Higher scores in the ‘feed, water and supply of equipment’ and
‘environment and region’ categories tended to reduce the odds of potentiated sulphonamide
use (p < 0.1).
Table 2. Summary of multivariable linear regression models for total antimicrobial use (AMU) (TItotal), group oral AMU
(TIgroup), individual AMU (TIindividual) and cephalosporin/fluoroquinolone use (TIceflq). The outcome variables are
expressed as treatment incidence (TI200) and were log-transformed prior to analysis. Both the coefficients on the log scale
and the back-transformed estimates are presented.
Outcome Variable Predictor Variables Estimate a Std. Error Back-TransformedEstimate (95% CI) p
LOG TItotal Intercept 3.28 0.936 26.48
adjusted R2 = 0.53 Finisher mortality_2016 0.28 0.135 1.32 (1.01–1.74) 0.043
p < 0.001 Home milling (ref = no) −1.08 0.265 0.34 (0.2–0.58) 0.000
Weaner stage (days) −0.03 0.013 0.97 (0.95–1) 0.027
IAv vaccination (ref = no) 1.06 0.272 2.88 (1.66–4.97) 0.000
Lung abscesses (%) 0.07 0.037 1.07 (0.99–1.16) 0.070
Pericarditis (%) 0.06 0.031 1.06 (1–1.13) 0.059
LOG TIgroup Intercept 2.93 0.832 18.72
adjusted R2 = 0.55 Finisher mortality 0.28 0.120 1.33 (1.04–1.69) 0.023
p < 0.001 Home milling (ref = no) −0.97 0.235 0.38 (0.23–0.61) 0.000
Weaner stage (days) −0.02 0.011 0.98 (0.95–1) 0.041
IAv vaccination (ref = no) 0.95 0.242 2.58 (1.58–4.19) 0.000
Lung abscesses (%) 0.07 0.033 1.07 (1–1.14) 0.046
Pericarditis (%) 0.06 0.028 1.06 (1–1.12) 0.037
LOG TIindividual Intercept −0.58 0.473 0.56
adjusted R2 = 0.29
Feed, water and equipment
supply b −0.01 0.007 0.99 (0.97–1) 0.048
p < 0.001 Vermin and bird control b 0.01 0.005 1.01 (1–1.02) 0.018
Piglet prophylaxis (ref = no) c 0.60 0.192 1.82 (1.23–2.67) 0.003
Liver milk spots (%) 0.01 0.004 1.01 (1–1.02) 0.018
LOG TIceflq Intercept −1.32 0.816 0.27
adjusted R2 = 0.37 Weaner mortality −0.41 0.126 0.66 (0.51–0.85) 0.002
p < 0.001 Feed, water and equipmentsupply b −0.03 0.012 0.97 (0.95–1) 0.031
Sow prophylaxis (ref = no) c 0.72 0.378 2.06 (0.96–4.41)
Piglet prophylaxis (ref = no) c 1.16 0.350 3.19 (1.58–6.45) 0.002
Pericarditis (%) 0.14 0.041 1.15 (1.06–1.25) 0.001
Constants were added to the TIindividual and TIceflq (1 and 0.01, respectively) before log transformation. The back-transformed estimates
refer to the multiplicative effect per unit change of predictor variable. For example, farms vaccinating against IAv had 2.88 times higher
treatment incidence than farms not vaccinating. a Log scale. b Biocheck.UgentTM biosecurity score. c Prophylactic antimicrobial use.
Legend: CI—confidence interval; TI—treatment incidence; IAv—influenza A virus.
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Table 3. Summary of multivariable logistic regression models investigating risk factors for oral group antimicrobial treatment with various antimicrobial classes on Irish farrow-to-finish
pig farms (n = 52) during 2016. Predictor variables with p ≤ 0.1 were retained in the final models. Results are presented as odds ratios with 95% confidence intervals.
Outcome Variables: Oral Group Treatment with Antimicrobial Class
Tetracyclines PotentiatedSulphonamides Penicillins Macrolides Lincosamides Amphenicols Aminoglycosides Polymyxins
Predictor Variable OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Herd characteristics
Home milling (ref = no) 0.16 (0.02–0.86) - - - - - - -
Finisher mortality (%) - 7.7 (1.7–88.88) - 2.81 (1.32–7.18) - - - -
Age at weaning (days) - - - 1.32 (1.05–1.78) - - - -
Weaner stage (days) 0.89 (0.78–0.98) 0.69 (0.45–0.87) - - 0.9 (0.8–0.98) - - -
Finisher stage (days) - - - - - - 1.07 (1–1.16) -
No. of sows per employee - - - - - - 0.98 (0.95–1.00) 1.02 (1–1.04)
Farmer experience (years) - - - - - - 1.08 (1.00–1.18) -
Youngest building (years) - - - - 1.3 (1.07–1.68) - - -
Biosecurity scores
Feed, water and equipment
supply - 0.92 (0.82–1.00) - - - - - -
Environment and region - 0.95 (0.87–1.00) - - - - - -
Nursery unit management 0.93 (0.87–0.99) - - - - - - -
Measures between compartments
and use of equipment - - - - - - - 0.94 (0.89–0.99)
Pluck lesions at slaughter and
disease status
Pleurisy (%) - 1.11 (1.03–1.25) - - - - - -
Moderate/severe pleurisy (%) - - - - - - 0.89 (0.81–0.96) -
Scars (%) 1.13 (1.02–1.3) - - - - - 1.1 (1.02–1.23) -
Lung abscesses (%) - - - - - 1.47 (1.09–2.9) - -
Pericarditis (%) - - 1.35 (1.11–1.73) - - - - 1.19 (1.01–1.44)
Liver milk spots (%) - - - - - 1.04 (1–1.11) - -
IAv status (ref = negative) - - 0.11 (0.01–0.74) - - - - -
Mhyo status (ref = negative) - - - - 134.31(4.66–>9999) - - -
PRRSv status (ref = negative) - - - - - 270.67(5.26–>9999) - -
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Table 3. Cont.
Outcome Variables: Oral Group Treatment with Antimicrobial Class
Tetracyclines PotentiatedSulphonamides Penicillins Macrolides Lincosamides Amphenicols Aminoglycosides Polymyxins
Vaccination and prophylactic
antimicrobial use practices




(4.8–191.38) - - - -
Piglet prophylaxis (ref = no) - - 10.18(2.22–64.81) - -
11.3
(1.09–367.08) - -
To aid readability of the table, p-values are omitted. A full version of the table including p-values is available in the Supplementary Material, Table S7. Legend: OR-odds ratio; CI-confidence interval;
IAv—influenza A virus; Mhyo—Mycoplasma hyopneumoniae; PRRSv—porcine respiratory and reproductive syndrome virus.
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The results from the final logistic regression models for AM classes used as individ-
ual treatments are summarised in Table 4 and Supplementary Table S8. All farms used
injectable penicillins (41.7% of all individual treatments), and thus this class was excluded
from the analysis. There was a tendency for increased odds of injectable tetracycline use
on farms with higher weaner mortality (p = 0.072). Farms with higher piglet or finisher
mortality tended to be less likely to use injectable macrolides (p < 0.1). The number of
sows per employee was positively associated with the use of injectable aminoglycosides
and third-generation cephalosporins (p < 0.05). Higher scores in the biosecurity categories
‘disease management’ and ‘feed, water and supply of equipment’ were associated with de-
creased odds of tetracycline use (p = 0.08) and fluoroquinolone use (p = 0.028), respectively.
However, a number of biosecurity categories were associated with increased odds of use
for certain AM classes. Farms with higher prevalence of liver milk spot lesions were less
likely to use tetracyclines (p = 0.021) but more likely to use lincosamides (p = 0.017). In
agreement with the findings for the TIceflq model, farms that administered prophylactic
AM treatments to piglets were 4 times more likely to use third-generation cephalosporins
(p = 0.074), and those that administered prophylactic AMs to sows were 17 times more
likely to use fluoroquinolones (p = 0.088).
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Table 4. Summary of multivariable logistic regression models investigating risk factors for individual antimicrobial treatment with various antimicrobial classes on Irish farrow-to-finish
pig farms (n = 52) during 2016. Results are presented as odds ratios with 95% confidence intervals.
Outcome Variables: Individual Treatment with Antimicrobial Class
Tetracyclines PotentiatedSulphonamides Macrolides Lincosamides Aminoglycosides Aminocyclitols Fluoroquinolones Cephalosporins
Predictor variable OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Herd characteristics
Piglet mortality (%) - - 0.77 (0.57–0.98) - - - - -
Weaner mortality (%) 1.78 (1.04–3.66) - - - - - - -
Finisher mortality (%) - - 0.52 (0.22–1.04) - - - - -
Average daily gain (g) - - - 1.02 (1–1.03) - - - 0.99 (0.97–1)
Feed conversion ratio 0 (0–0.15) - - - - - - -
Pigs per sow per year - - - - 0.43 (0.2–0.73) 0.61 (0.38–0.89) - -
Weaning age (days) - 0.72 (0.5–0.95) - - 0.79 (0.6–0.97) - - -
Total rearing period (days) - - - - - 0.91 (0.83–0.97) - -
No. of sows per employee - - - - 1.04 (1.01–1.07) - - 1.03 (1.01–1.06)
Biosecurity scores
Transport of animals, removal of
manure and dead animals - - 1.11 (1.03–1.23) - - - - -
Feed, water and equipment
supply - - - - - - 0.9 (0.8–0.97) -
Vermin and bird control - 1.08 (1.02–1.19) - - - - - -
Disease management 0.97 (0.93–1.00) - - - - - - -
Fattening unit management 1.06 (1.01–1.13) 1.07 (1.01–1.16) - - - - - -
Overall internal biosecurity - - - - - 1.06 (1.01–1.13) - -
Pluck lesions at slaughter and
disease status
Pericarditis (%) - - - - - 0.82 (0.65–0.98) 1.59 (1.11–2.67) -
Liver milk spots (%) 0.96 (0.93–0.99) - - 1.04 (1.01–1.07) - - - -
IAv status (ref = negative) - - - - 0.07 (0–0.51) - - -
Vaccination and prophylactic
antimicrobial use practices
IAv vaccination (ref = no) - - - 8.18 (1.8–50.29) - - - -
PRRSv vaccination (ref = no) - - - 7.27 (1.54–45.87) - - - -
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Table 4. Cont.
Outcome Variables: Individual Treatment with Antimicrobial Class
Tetracyclines PotentiatedSulphonamides Macrolides Lincosamides Aminoglycosides Aminocyclitols Fluoroquinolones Cephalosporins
Piglet prophylaxis (ref = no) - 0.01 (0–0.21) - - - - - 4.35 (0.96–26.2)
Sow prophylaxis (ref = no) - - - - - - 17.22(1.15–1032.14) -
To aid readability of the table, p-values are omitted. A full version of the table including p-values is available in the Supplementary Material, Table S8. Legend: OR-odds ratio; CI-confidence interval;
IAv—influenza A virus; PRRSv—porcine respiratory and reproductive syndrome virus.
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4. Discussion
This study explored the risk factors for AMU on Irish pig farms using data collected
during previously published studies investigating AMU, biosecurity and respiratory dis-
ease on Irish pig farms [47,52,53]. The study farms were clients of the Teagasc advisory
service and participated on a voluntary basis. This may have introduced selection bias,
where farms with a prior interest in improving herd health were more likely to enrol, and
therefore it cannot be assumed that the study sample is representative of the entire industry.
Nevertheless, it represented approximately 29% of the national herd, and the findings
of this investigation provide useful insights into the drivers for AMU in the commercial
pig sector in Ireland. The linear regression models identified the main risk factors for the
amounts of AMs used overall and for the primary modes of administration (group oral
and individual), as well as for the fluoroquinolone and third-generation cephalosporin
classes. The latter category is of interest due to the importance of these classes to public
health and concerns over resistance [63,64], as well as the fact that, although volumes
are relatively low, use is observed on most Irish farms [47]. The models for all AMU
(TItotal) and oral group treatments (TIgroup) provided similar results because the majority
of treatments are administered orally, particularly via medicated feed. Individual AMU
and cephalosporin/fluoroquinolone use also had risk factors in common, which is un-
surprising since cephalosporins (injectable) and fluoroquinolones (injectable or oral dose)
are relatively common individual treatments. The logistic regression models identified a
number of risk factors for the use of certain combinations of administration route and class
of AM. It should be noted that these models did not distinguish between low or high use,
for example, the absence of use of a particular AM does not imply less AMU overall as
another class may be used in its stead. For ease of interpretation, the results are discussed
below in terms of the broad categories of risk factors.
4.1. Farm Characteristics
Farms home milling at least one of their diets had approximately 66% lower AMU
than those that purchased all their feed. In particular, they were less likely to use group
tetracycline treatment (p = 0.048), which was the most widely and heavily used oral
treatment. This may relate to structural differences in AM delivery as home milling farms
are not permitted to manufacture medicated feed unless they also possess a licence to do
so [65]. Therefore, while home milling farms still have access to AMs, the “ease” of access
differs between both groups, and this may point to a social factor whereby convenience
and habit could explain some of the routine prophylactic AMU in medicated feed practised
on the study farms. On the other hand, home milling may confer health benefits as they are
reported to have lower finisher mortality compared to those purchasing their feed [66]. The
reasons for this are not clear but could relate to the diet form, for example, lower prevalence
of Brachyspira piloscoli was reported for Danish farms that provided home-milled or non-
pelleted feed [67].
Older weaning age has been associated with lower AMU on European farms [17,24],
likely because older piglets are less susceptible to the associated stresses of moving, mixing
and diet change [68,69]. In this study, farms with a later weaning age were more likely
to use macrolide group treatments (p = 0.037), but weaning age was not associated with
the quantity of AMU. The reason for the association with macrolide use is not obvious,
but the lack of association with quantitative AMU is likely due to insufficient variability
between farms as most of them weaned pigs at 29 days. After weaning, the weaner stage
on Irish farms is typically split into two sections, roughly 4–5 weeks each, with different
housing and feeding infrastructure. Medicating throughout both phases was common on
the studied farms. Contrary to the authors’ belief that a longer weaner phase might be
associated with increased AMU, farms with a longer stay in the weaner stage had lower
AMU. These farms were less likely to use oral tetracyclines or potentiated sulphonamides,
the classes that contributed most to overall use, and they were also less likely to use oral
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lincosamides. The contrary results could relate to differences in accommodation associated
with a longer weaning phase.
Farms with a higher number of sows per employee were more likely to use polymyxins
(colistin) (p = 0.072) and cephalosporins (ceftiofur) (p = 0.029). Conversely, such farms were
less likely to use oral aminoglycosides (apramycin) (p = 0.035). Colistin and apramycin
are primarily indicated for gastrointestinal disease [14], and the conflicting results here
may relate to the choice of one over the other on these farms when treating gastrointestinal
disease. Colistin and ceftiofur are both HP CIAs, and the observation that less well-staffed
farms are more likely to use them warrants closer inspection. These farms may have more
health problems due to a lack of staff and thus may be more inclined to use so-called ‘last
resort’ drugs. Convenience may be a factor too as the most widely used formulation of
ceftiofur is long-acting, although this association was not observed for other long-acting
parenteral AMs (e.g., macrolides).
4.2. Farm Performance Indicators
Finisher mortality is impacted by a variety of factors, including management, en-
vironment and infectious disease [70,71], and in this study, each additional 1% increase
in mortality was associated with 33% higher AMU. This association has been previously
demonstrated for the use of in-feed medication in Spain and the UK [26,72] and for AMU
on heavy pig-fattening farms in Italy [73]. Farms with higher finisher mortality were also
more likely to use oral potentiated sulphonamides or macrolides. Given that tetracyclines
were the most applied group treatments, this might indicate a greater likelihood to deviate
from the ‘standard’ use of tetracyclines. Since finishers accounted for just 10% of total
AMU, finisher mortality may also reflect overall health through all stages of production.
In this study, all farms that used medicated feed in finisher pigs also provided medicated
diets in the weaner stage, suggesting that these farms may also have health problems in the
earlier stages. Higher weaner mortality was associated with lower use of fluoroquinolones
and cephalosporins (TIceflq). It might be expected that weaner mortality would increase
the use of these drugs, but farms with higher weaner mortality due to infectious disease
may be more likely to focus on group treatments and, in this study, tended to have higher
odds of parenteral tetracycline use (p = 0.072).
4.3. Biosecurity Practices
In contrast to other European studies, there was no association between the internal,
external or overall biosecurity scores and total AMU [24,25]. Irish farms generally had
high external biosecurity scores, mainly because most farms are closed herds, neither
buying replacement gilts or finisher pigs from other sources. This may partly explain
the lack of association with AMU. However, farms with better scores in the biosecurity
category of ‘feed, water and equipment supply’ had lower use of individual treatments
including cephalosporins and fluoroquinolones, and they were also less likely to use
oral potentiated sulphonamides. Feed and water as well as their associated delivery and
storage are potential sources of pathogens [74]. There were other associations between
certain biosecurity categories and patterns of use. Better scores in the biosecurity category
‘measures between compartments’ were associated with lower odds of using polymyxins,
which may link poor biosecurity with gastrointestinal disease. Although biosecurity scores
were not associated with overall AMU in this study, there is evidence that farms which
improve their biosecurity can reduce their AMU [75,76]. The generally lower internal
biosecurity scores on Irish farms [52] demonstrate an opportunity for improvement, and
the PigHealthCheck initiative run by Animal Health Ireland, which provides for free
biosecurity assessments, is helping to raise awareness on this topic (https://animalhealthir
eland.ie/programmes/pig-healthcheck/introduction/ last accessed 20 September 2021).
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4.4. Respiratory Disease
Respiratory disease is an important cause of mortality in pig production [77] and
a major indication for AMU. In this study, neither farm status for IAv, PRRSv, Mhyo or
APP, nor the prevalence of pneumonia or pleurisy were directly associated with total or
group AMU. Instead, pericarditis and lung abscesses were positively associated with AMU,
which increased by 7% and 6% respectively, for each percentage increase in farm preva-
lence. Pericarditis was also associated with higher fluoroquinolone use (approximately
15%) and higher odds of oral penicillin use (p = 0.007). Fluoroquinolones and penicillins
are both are indicated for the treatment of APP infection and the latter is often used to
treat and control Streptococcus suis infection [14]. Lung abscesses and pericarditis may
be extensions of pneumonia and/or pleurisy involving infection with APP, Pasteurella
multocida or Streptococcus suis [78], or they may be sequelae of systemic infections such
as S. suis or Glaesserella parasuis. Thus, these lesions may be indicators of general health
on the farm as S. suis and G. parasuis are also implicated in meningitis, polyserositis and
arthritis, which are common conditions in pigs post-weaning [79,80]. Higher individual
AMU associated with increased prevalence of liver milk spots at slaughter may be a direct
result of Ascaris suum infestation, or it may indicate deficiencies in farm hygiene. Ascaris
suum infestation has also been shown to interfere with Mhyo vaccination [81], further
highlighting the importance of parasite control on pig farms.
4.5. Disease Management
Farms that administered prophylactic AM treatments to piglets had approximately
82% higher individual AMU (TIindividual), higher use of cephalosporins and/or fluo-
roquinolones (TIceflq) and they were also 10 times more likely to use oral penicillins
(p = 0.006). Prophylactic AMU in piglets was observed on 50% of the study farms and is
also common in other countries [82,83]. It usually occurs in the first week of life alongside
procedures such as teeth clipping, tail docking and iron injection. The purpose of these
treatments is to prevent infections associated with these procedures or with neonatal dis-
eases endemic to the farm (e.g., meningitis or colibacillosis). Amoxicillin injection was
the most common treatment used, but ceftiofur, enrofloxacin and long-acting macrolides
were also used. The association with oral penicillin use might indicate farms using both
strategies to control S. suis infection. Whether these treatments reduce morbidity and
mortality on these farms is unknown; however, this finding shows that the practice does
not reduce AMU. Farms that administered prophylactic treatments to sows tended to use
more fluoroquinolones in growing pigs. This may reflect the disease status on certain
farms or perhaps a behavioural pattern, where injudicious AMU practices co-occur on
some farms (or it may reflect the corollary: good antimicrobial stewardship on some farms
neither practising prophylaxis nor using HP CIAs). Farms vaccinating against IAv had
2.9 times higher TItotal compared to non-vaccinating farms. A similar association was
observed in French herds in the pan-European study carried out by Collineau et al., who
also reported other positive associations between vaccination and AMU for a number of
country/pathogen combinations [17]. In Denmark, a retrospective study investigating
trends in AMU and vaccination between 2007 and 2013 found no link between increased
vaccination and reduction in AMU that occurred during this period [84], while others
found that vaccination was associated with higher AMU [34,35]. This may seem counter-
intuitive, but the authors of these studies suggest that farmers may use vaccinations to
control diseases that are already on the farm in conjunction with AMs, while conversely,
farms free from a given disease do not need to vaccinate and may not need AMs. In the
present study, higher AMU on farms vaccinating against IAv may be a consequence of more
severe respiratory disease. An association between influenza and pleurisy was reported for
the larger cohort of Irish farms [53] and by others [85]. Co-infection is a common feature of
the Porcine Respiratory Disease Complex (PRDC), and often, these co-infections are syner-
gistic [86]. It is noteworthy that 11 of the 19 farms vaccinating against IAv also vaccinated
against PRRSv. This is an interesting observation given that Calderon Diaz et al. found
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that Irish farms vaccinating against IAv or PRRSv are less profitable than farms that were
positive but not vaccinating [87]. This could suggest that farms with high AMU are also
less profitable, but further research is required. These findings highlight that vaccination
alone may not be enough to eliminate disease and reduce AMU. However, their proven
efficacy against a range of porcine infectious diseases [31–33] means that they are a key
tool in this regard [28].
4.6. Implications for Irish Pig Sector
Prophylaxis was one of the main drivers of AMU in this study. This was seen in the
relationship between AMU and home milling and in the influence that prophylactic prac-
tices in sows and piglets had on the use of oral penicillins and HP CIAs. European Union
regulations from 2022 mean that prophylactic AMU in animals will be banned in almost all
circumstances, and metaphylactic treatments (group treatments in the presence of disease)
and the use of certain AMs, likely the EMA category B drugs [64], will only be allowed
where clearly justified [88]. This will require significant changes in management practices
on Irish farms as well as veterinary prescribing practices. One feature of prophylactic use is
that it may happen whether disease is present or not. This presents an opportunity in that
unnecessary use is easier to eliminate and sizeable reductions have been achieved in some
countries with similar patterns of AMU, such as the United Kingdom, in recent years [89].
Reducing the need for AMU is more challenging, however, requiring improvements in
overall herd health. Irish farmers previously identified economic concerns over interna-
tional competition and cost effectiveness of alternatives to AMU as barriers to reducing
in-feed medication [40], and there were similar findings amongst British farmers, where
high investment costs and staffing difficulties were cited as barriers [30]. Nevertheless, this
challenge has been met in other countries [90,91] and can be achieved without impacting
performance or profit [92–94]. One challenge facing farmers is the forthcoming ban on the
use of zinc oxide in the EU from 2022 [95]. In common with other countries such as Den-
mark [96], zinc oxide is widely used to control gastroenteritis on Irish farms: all but one of
the study farms used it in at least one diet in 2016 (data not shown). Data on the prevalence
of porcine gastrointestinal disease in Ireland are lacking and none were available for use
in this study. Therefore, it is unknown how gastrointestinal disease influences AMU on
Irish pig farms and future research would be of benefit. This study shows where some
improvements could be made to help farms reduce AMU. Further research is needed to
explore if farms practising home milling have advantages in management or nutrition that
can be applied to other farms. Farms should ensure they have adequate parasite control
regimens in place. High farm prevalence of pericarditis warrants a detailed investigation
since there are multiple aetiologies, and indeed this is a poorly researched topic. The
structure of the Irish pig industry presents some advantages in terms of AMU, many of
which have not been utilised. Firstly, the sector is relatively small—there are approximately
300 commercial pig farms in Ireland. This means that potential targeted interventions to aid
a reduction in AMU, for example farms with high prevalence of pericarditis, would involve
a small number of farms. Secondly, almost all herds are closed, meaning that neither
gilts nor fattening pigs are purchased from other farms. These practices (i.e., purchase of
animals) have been associated with increased respiratory disease [97] and mortality [98].
While AMU and respiratory disease are not lower in Ireland at present, the structure of the
industry may make it easier to sustain any improvements it can make.
5. Conclusions
This study identified prophylactic use and respiratory disease as the main drivers
for antimicrobial use in Irish pig production. Farms that milled their own feed had lower
AMU, while farms with higher prevalence of pericarditis, lung abscesses and liver milk
spot lesions, as well as with higher finisher mortality, and those vaccinating for IAv had
higher AMU. Farms that administered prophylactic AM treatments to sows or piglets
had higher use of HP CIAs. These findings highlight areas of farm management where
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interventions may aid in reducing AMU on Irish pig farms, although further investigations
at the individual farm level and in the wider population are required.
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scores evaluated using the Biocheck.UGent™ questionnaire from 52 Irish farrow-to-finish pig farms in
2016. Table S3: Summary of prevalence of pluck lesions and disease status on 52 Irish farrow-to-finish
pig farms. Table S4: Summary of vaccination and prophylactic antimicrobial use practices on 52 Irish
farrow-to-finish pig farms during 2016. Table S5: Summary of p-values for the univariable linear
regression models investigating risk factors for antimicrobial use (AMU) on 52 Irish farrow-to-finish
pig farms during 2016. Table S6: Summary of univariable associations between a range of risk factors
and the use of various antimicrobial classes via oral group or individual modes of treatment on
52 Irish farrow-to-finish pig farms during 2016. Table S7: Summary of multivariable logistic regression
models investigating risk factors for oral group antimicrobial treatment with various antimicrobial
classes on Irish farrow-to-finish pig farms (n = 52) during 2016 (this is a companion to Table 3).
Table S8: Summary of multivariable logistic regression models investigating risk factors for oral
group antimicrobial treatment with various antimicrobial classes on Irish farrow-to-finish pig farms
(n = 52) during 2016 (this is a companion to Table 4).
Author Contributions: L.O. drafted the manuscript and performed the data analysis and data
visualisation; L.O., M.R.d.C., J.A.C.D. and E.G.M. performed the data collection in the field; M.R.d.C.
carried out the pluck lesion evaluation and collection of blood samples; L.O., J.A.C.D., S.O. and
E.G.M. designed the study; L.O., J.A.C.D. and E.G.M. performed the statistical analysis; E.G.M. and
F.C.L. were responsible for the conceptualisation and design of, and funding acquisition for, the
cross-sectional studies on which this investigation is based; L.O., M.R.d.C., J.A.C.D., F.C.L. and E.G.M.
reviewed and edited the manuscript. All authors have read and agreed to the published version of
the manuscript.
Funding: This study was conducted within the AMURAP project (Antimicrobial Use and Resistance
in Animal Production) which investigates AMU and AMR in the Irish pig and poultry industries. This
project is funded by the Irish Department of Agriculture Food and the Marine (grant reference number
15 S 676). The studies investigating biosecurity and respiratory disease were funded by the Irish
Department of Agriculture, Food and the Marine under the Research Stimulus Fund (PathSurvPig 14
S 832). The funders had no role in the study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Institutional Review Board Statement: The participating farmers gave informed written consent
for the use of their data in this study on condition of anonymity. This research did not involve the
use of animal subjects. Thus, formal approval by an ethics committee was not required under Irish
regulations.
Informed Consent Statement: The participating farmers gave informed written consent for the use
of their data in this study on condition of anonymity.
Data Availability Statement: The datasets used and/or analysed during the current study are
available from the corresponding author upon reasonable request.
Acknowledgments: The authors would like to thank the participating farmers, their private veteri-
nary practitioners and the staff at participating slaughterhouses for their cooperation with this study.
The authors would also like to thank the pig development officers in the Teagasc Pig Development
Department for their advice and assistance with farm recruitment, farm visits and data collection.
James Gibbons is acknowledged for his role in funding acquisition for the AMURAP project and its
initiation. Finally, we would like to thank Rose Fitzgerald from the Munster Technological University
for assisting with the serological testing.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the
design, execution, interpretation, or writing of the study.
Animals 2021, 11, 2828 19 of 23
References
1. World Health Organisation. Global Action Plan on Antimicrobial Resistance. 2015. Available online: https://apps.who.int/iris/
bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1 (accessed on 2 April 2021).
2. Department of Health. Ireland’s National Action Plan on Antimicrobial Resistance 2017–2020. (iNAP). 2017. Available on-
line: https://www.agriculture.gov.ie/media/migration/animalhealthwelfare/amr/inap/IrelandNationalActionPlanAntimic
robialResistance030818.pdf (accessed on 2 December 2020).
3. European Commission. A European One Health Action Plan against Antimicrobial Resistance (AMR). 2017. Available online:
https://ec.europa.eu/health/amr/sites/health/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf (accessed on 2
April 2021).
4. Tiseo, K.; Huber, L.; Gilbert, M.; Robinson, T.P.; van Boeckel, T.P. Global Trends in Antimicrobial Use in Food Animals from 2017
to 2030. Antibiotics 2020, 9, 918. [CrossRef]
5. Aarestrup, F.M. The Livestock Reservoir for Antimicrobial Resistance: A Personal View on Changing Patterns of Risks, Effects of
Interventions and the Way Forward. Phil. Trans. R. Soc. B 2015, 370, 20140085. [CrossRef]
6. Tang, K.L.; Caffrey, N.P.; Nóbrega, D.B.; Cork, S.C.; Ronksley, P.E.; Barkema, H.W.; Polachek, A.J.; Ganshorn, H.; Sharma, N.;
Kellner, J.D.; et al. Restricting the Use of Antibiotics in Food-Producing Animals and Its Associations with Antibiotic Resistance in
Food-Producing Animals and Human Beings: A Systematic Review and Meta-Analysis. Lancet Planet. Health 2017, 1, e316–e327.
[CrossRef]
7. DANMAP (Danish Integrated Antimicrobial Resistance Monitoring and Research Programme). DANMAP 2019—Use of
Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria From Food Animals, Food and Humans in
Denmark. 2020. Available online: https://www.danmap.org/reports/2019 (accessed on 23 January 2021).
8. The Netherlands Veterinary Medicines Institute. Usage of Antibiotics in Agricultural Livestock in The Netherlands in 2018. Trends
and Benchmarking of Livestock Farms and Veterinarians. 2020. Available online: https://cdn.i-pulse.nl/autoriteitdiergeneesmid
delen/userfiles/EN/SDa-rapporten/sda-rapport-usage-of-antibiotics-in-agricultural-livestock-in-2019-corr-fig5b.(1).pdf (ac-
cessed on 23 January 2021).
9. Belvet-SAC. Belgian Veterinary Surveillance of Antibacterial Consumption National Consumption Report 2019. 2020. Available
online: https://belvetsac.ugent.be/BelvetSac_report_2019.pdf (accessed on 23 January 2021).
10. Sjölund, M.; Postma, M.; Collineau, L.; Lösken, S.; Backhans, A.; Belloc, C.; Emanuelson, U.; Beilage, E.G.; Stärk, K.; Dewulf, J.
Quantitative and Qualitative Antimicrobial Usage Patterns in Farrow-to-Finish Pig Herds in Belgium, France, Germany and
Sweden. Prev. Vet. Med. 2016, 130, 41–50. [CrossRef] [PubMed]
11. Sarrazin, S.; Joosten, P.; Gompel, L.V.; Luiken, R.E.C.E.; Mevius, D.J.; Wagenaar, J.A.; Heederik, D.J.J.J.; Dewulf, J. Quantitative and
Qualitative Analysis of Antimicrobial Usage Patterns in 180 Selected Farrow-to-Finish Pig Farms from Nine European Countries
Based on Single Batch and Purchase Data. J. Antimicrob. Chemother. 2019, 74, 807–816. [CrossRef] [PubMed]
12. Schwarz, S.; Kehrenberg, C.; Walsh, T.R. Use of Antimicrobial Agents in Veterinary Medicine and Food Animal Production. Int. J.
Antimicrob. Agents 2001, 17, 431–437. [CrossRef]
13. Prescott, J.F. Antimicrobial Use in Food and Companion Animals. Anim. Health Res. Rev. 2008, 9, 127–133. [CrossRef] [PubMed]
14. Burch, D.G. Antimicrobial drug use in swine. In Antimicrobial Therapy in Veterinary Medicine; Giguère, S., Prescott, J.F., Dowling,
P.M., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, USA, 2013; pp. 553–568. ISBN 9780470963029.
15. Jensen, V.; Eorg, H.; Aarestrup, F. Indications and Patterns of Therapeutic Use of Antimicrobial Agents in the Danish Pig
Production from 2002 to 2008. J. Vet. Pharmacol. Ther. 2012, 35, 33–46. [CrossRef]
16. Van Rennings, L.; von Münchhausen, C.; Ottilie, H.; Hartmann, M.; Merle, R.; Honscha, W.; Käsbohrer, A.; Kreienbrock, L.
Cross-Sectional Study on Antibiotic Usage in Pigs in Germany. PLoS ONE 2015, 10, e0119114. [CrossRef]
17. Collineau, L.; Bougeard, S.; Backhans, A.; Dewulf, J.; Emanuelson, U.; Beilage, G.E.; Lehébel, A.; Lösken, S.; Postma, M.; Sjölund,
M.; et al. Application of Multiblock Modelling to Identify Key Drivers for Antimicrobial Use in Pig Production in Four European
Countries. Epidemiol. Infect. 2018, 146, 1003–1014. [CrossRef]
18. Kruse, A.; Kristensen, C.; Lavlund, U.; Stege, H. Antimicrobial Prescription Data in Danish National Database Validated against
Treatment Records in Organic Pig Farms and Analysed for Associations with Lesions Found at Slaughter. BMC Vet. Res. 2019, 15,
218. [CrossRef]
19. Vieira, A.R.; Pires, S.M.; Houe, H.; Emborg, H.-D. Trends in Slaughter Pig Production and Antimicrobial Consumption in Danish
Slaughter Pig Herds, 2002–2008. Epidemiol. Infect. 2010, 139, 1601–1609. [CrossRef] [PubMed]
20. Van der Fels-Klerx, H.; Puister-Jansen, L.; van Asselt, E.; Burgers, S. Farm Factors Associated with the Use of Antibiotics in Pig
Production. J. Anim. Sci. 2011, 89, 1922–1929. [CrossRef]
21. Hemme, M.; Ruddat, I.; Hartmann, M.; Werner, N.; van Rennings, L.; Käsbohrer, A.; Kreienbrock, L. Antibiotic Use on German
Pig Farms—A Longitudinal Analysis for 2011, 2013 and 2014. PLoS ONE 2018, 13, e0199592. [CrossRef] [PubMed]
22. Arnold, C.; Schüpbach-Regula, G.; Hirsiger, P.; Malik, J.; Scheer, P.; Sidler, X.; Spring, P.; Peter-Egli, J.; Harisberger, M. Risk
Factors for Oral Antimicrobial Consumption in Swiss Fattening Pig Farms—A Case–Control Study. Porc. Health Manag. 2016, 2, 5.
[CrossRef]
23. Raasch, S.; Postma, M.; Dewulf, J.; Stärk, K.; Beilage, E.G. Association between Antimicrobial Usage, Biosecurity Measures as
Well as Farm Performance in German Farrow-to-Finish Farms. Porc. Health Manag. 2018, 4, 30. [CrossRef] [PubMed]
Animals 2021, 11, 2828 20 of 23
24. Postma, M.; Backhans, A.; Collineau, L.; Loesken, S.; Sjölund, M.; Belloc, C.; Emanuelson, U.; Beilage, E.G.; Nielsen, E.; Stärk,
K.D.; et al. Evaluation of the Relationship between the Biosecurity Status, Production Parameters, Herd Characteristics and
Antimicrobial Usage in Farrow-to-Finish Pig Production in Four EU Countries. Porc. Health Manag. 2016, 2, 9. [CrossRef]
[PubMed]
25. Laanen, M.; Persoons, D.; Ribbens, S.; de Jong, E.; Callens, B.; Strubbe, M.; Maes, D.; Dewulf, J. Relationship between Biosecurity
and Production/Antimicrobial Treatment Characteristics in Pig Herds. Vet. J. 2013, 198, 508–512. [CrossRef]
26. Casal, J.; Mateu, E.; Mejía, W.; Martín, M. Factors Associated with Routine Mass Antimicrobial Usage in Fattening Pig Units in a
High Pig-Density Area. Vet. Res. 2007, 38, 481–492. [CrossRef]
27. EMA (European Medicines Agency); EFSA (European Food Safety Authority). EMA and EFSA Joint Scientific Opinion on
measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts
on food safety (RONAFA). EFSA J. 2017, 15, 4666. [CrossRef]
28. Postma, M.; Stärk, K.; Sjölund, M.; Backhans, A.; Beilage, E.; Lösken, S.; Belloc, C.; Collineau, L.; Iten, D.; Visschers, V.; et al.
Alternatives to the Use of Antimicrobial Agents in Pig Production: A Multi-Country Expert-Ranking of Perceived Effectiveness,
Feasibility and Return on Investment. Prev. Vet. Med. 2015, 118, 457–466. [CrossRef]
29. Dupont, N.; Diness, L.H.; Fertner, M.; Kristensen, C.S.; Stege, H. Antimicrobial Reduction Measures Applied in Danish Pig Herds
Following the Introduction of the “Yellow Card” Antimicrobial Scheme. Prev. Vet. Med. 2017, 138, 9–16. [CrossRef]
30. Coyne, L.A.; Latham, S.M.; Dawson, S.; Donald, I.J.; Pearson, R.B.; Smith, R.F.; Williams, N.J.; Pinchbeck, G.L. Exploring
Perspectives on Antimicrobial Use in Livestock: A Mixed-Methods Study of UK Pig Farmers. Front. Vet. Sci. 2019, 6, 257.
[CrossRef] [PubMed]
31. Bak, H.; Rathkjen, P.H. Reduced Use of Antimicrobials after Vaccination of Pigs against Porcine Proliferative Enteropathy in a
Danish SPF Herd. Acta Vet. Scand. 2009, 51, 1. [CrossRef]
32. Kristensen, C.; Baadsgaard, N.; Toft, N. A Meta-Analysis Comparing the Effect of PCV2 Vaccines on Average Daily Weight Gain
and Mortality Rate in Pigs from Weaning to Slaughter. Prev. Vet. Med. 2011, 98, 250–258. [CrossRef] [PubMed]
33. Sacristán, R.D.P.; Michiels, A.; Martens, M.; Haesebrouck, F.; Maes, D. Efficacy of Vaccination against Actinobacillus Pleurop-
neumoniae in Two Belgian Farrow-to-Finish Pig Herds with a History of Chronic Pleurisy. Vet. Rec. 2014, 174, 302. [CrossRef]
[PubMed]
34. Temtem, C.; Kruse, A.; Nielsen, L.; Pedersen, K.; Alban, L. Comparison of the Antimicrobial Consumption in Weaning Pigs in
Danish Sow Herds with Different Vaccine Purchase Patterns during 2013. Porc. Health Manag. 2016, 2, 23. [CrossRef] [PubMed]
35. Kruse, A.; Kristensen, C.; Nielsen, L.; Alban, L. A Register-Based Study on Associations between Vaccination, Antimicrobial Use
and Productivity in Conventional Danish Finisher Pig Herds during 2011 to 2014. Prev. Vet. Med. 2019, 164, 33–40. [CrossRef]
36. Backhans, A.; Sjölund, M.; Lindberg, A.; Emanuelson, U. Antimicrobial Use in Swedish Farrow-to-Finish Pig Herds Is Related to
Farmer Characteristics. Porc. Health Manag. 2016, 2, 18. [CrossRef] [PubMed]
37. Visschers, V.; Postma, M.; Sjölund, M.; Backhans, A.; Collineau, L.; Loesken, S.; Belloc, C.; Dewulf, J.; Emanuelson, U.; Beilage,
G.E.; et al. Higher Perceived Risk of Antimicrobials Is Related to Lower Antimicrobial Usage among Pig Farmers in Four
European Countries. Vet. Rec. 2016, 179, 490. [CrossRef]
38. Moreno, M.A. Opinions of Spanish Pig Producers on the Role, the Level and the Risk to Public Health of Antimicrobial Use in
Pigs. Res. Vet. Sci. 2014, 97, 26–31. [CrossRef] [PubMed]
39. Visschers, V.H.M.; Backhans, A.; Collineau, L.; Iten, D.; Loesken, S.; Postma, M.; Belloc, C.; Dewulf, J.; Emanuelson, U.; Grosee
Beilage, E.; et al. Perceptions of Antimicrobial Usage, Antimicrobial Resistance and Policy Measures to Reduce Antimicrobial
Usage in Convenient Samples of Belgian, French, German, Swedish and Swiss Pig Farmers. Prev. Vet. Med. 2015, 119, 10–20.
[CrossRef] [PubMed]
40. Diana, A.; Snijders, S.; Rieple, A.; Boyle, L. Why Do Irish Pig Farmers Use Medications? Barriers for Effective Reduction of
Antimicrobials in Irish Pig Production. Ir. Vet. J. 2021, 74, 12. [CrossRef]
41. Ström, G.; Boqvist, S.; Albihn, A.; Fernström, L.-L.; Djurfeldt, A.A.; Sokerya, S.; Sothyra, T.; Magnusson, U. Antimicrobials in
Small-Scale Urban Pig Farming in a Lower Middle-Income Country—Arbitrary Use and High Resistance Levels. Antimicrob.
Resist. Infect. Control 2018, 7, 35. [CrossRef] [PubMed]
42. Isomura, R.; Matsuda, M.; Sugiura, K. An Epidemiological Analysis of the Level of Biosecurity and Animal Welfare on Pig Farms
in Japan and Their Effect on the Use of Veterinary Antimicrobials. J. Vet. Med. Sci. 2018, 80, 18–0287. [CrossRef]
43. Danish Veterinary and Food Administration. Guideline for Prescribing Antimicrobial for Pigs. 2018. Available online:
https://www.foedevarestyrelsen.dk/english/Animal/AnimalHealth/Veterinary_medicine/Documents/Antimicrobial%20
guideline%20for%20pigs%20Denmark%202018.pdf (accessed on 23 August 2021).
44. AMCRA. Vade-Mecum Pour Un Usage Responsable Des Produits Antibacteriens Chez Les Porcs. 2021. Available online:
https://formularium.amcra.be/a/3 (accessed on 23 August 2021).
45. Jensen, V.F.; Jorsal, S.-E.L.; Toft, N. A Cross-Sectional Study of Oral Antibacterial Treatment Patterns in Relation to Specific
Diarrhoeal Pathogens in Weaner Pigs. Vet. Microbiol. 2017, 203, 18–27. [CrossRef]
46. Sarrazin, S. Analysis of herd level antimicrobial usage in pigs and poultry in 9 European countries based on EFFORT data.
Presented to Quantification, Benchmarking and Stewardship of Veterinary Antimicrobial Usage. In Proceedings of the First
International Conference, Ghent University, Ghent, Belgium, 27 February 2018; Available online: https://aacting.org/first-aacti
ng-conference/ (accessed on 4 July 2021).
Animals 2021, 11, 2828 21 of 23
47. O’Neill, L.; da Costa, M.; Leonard, F.C.; Gibbons, J.; Díaz, J.; McCutcheon, G.; Manzanilla, E. Quantification, Description and
International Comparison of Antimicrobial Use on Irish Pig Farms. Porc. Heal Manag. 2020, 6, 30. [CrossRef]
48. Central Statistics Office (CSO). Pig Survey June 2017. 2017. Available online: https://www.cso.ie/en/releasesandpublications/er
/ps/pigsurveyjune2017/ (accessed on 2 December 2020).
49. Timmerman, T.; Dewulf, J.; Catry, B.; Feyen, B.; Opsomer, G.; de Kruif, A.; Maes, D. Quantification and Evaluation of Antimicrobial
Drug Use in Group Treatments for Fattening Pigs in Belgium. Prev. Vet. Med. 2006, 74, 251–263. [CrossRef]
50. European Medicines Agency. Defined Daily Doses for Animals (DDDvet) and Defined Course Doses for Animals (DCDvet) Euro-
pean Surveillance of Veterinary Antimicrobial Consumption (ESVAC). 2016. Available online: https://www.ema.europa.eu/en/d
ocuments/other/defined-daily-doses-animalsdddvet-defined-course-doses-animals-dcdvet-european-surveillance_en.pdf (ac-
cessed on 20 March 2020).
51. European Medicine Agency. Revised ESVAC Reflection Paper on Collecting Data on Consumption of Antimicrobial Agents
per Animal Species, on Technical Units of Measurement and Indicators for Reporting Consumption of Antimicrobial Agents in
Animals. 2013. Available online: https://www.ema.europa.eu/documents/scientific-guideline/revised-europeansurveillanc
e-veterinary-antimicrobial-consumption-esvac-reflection-papercollecting_en.pdf (accessed on 2 August 2019).
52. Rodrigues da Costa, M.; Gasa, J.; Díaz, J.A.C.; Postma, M.; Dewulf, J.; McCutcheon, G.; Manzanilla, E.G. Using the
Biocheck.UGentTM Scoring Tool in Irish Farrow-to-Finish Pig Farms: Assessing Biosecurity and Its Relation to Productive
Performance. Porc. Health Manag. 2019, 5, 4. [CrossRef]
53. Rodrigues da Costa, M.; Fitzgerald, R.; Manzanilla, E.; O’Shea, H.; Moriarty, J.; McElroy, M.C.; Leonard, F. A Cross-Sectional
Survey on Respiratory Disease in a Cohort of Irish Pig Farms. Ir. Vet. J. 2020, 73, 24. [CrossRef]
54. Madec, F.; Derrien, H. Fréquence, intensité et localisation des lésions pulmonaires chez le porc charcutier: Résultats d’une
premiére série d’observations en abattoir. Journées Rech. Porc. Fr. 1981, 13, 231–236.
55. Dottori, M.; Nigrelli, A.D.; Bonilauri, P.; Merialdi, G.; Gozio, S.; Cominotti, F. Proposta Di Un Nuovo Sistema Di Punteggiatura
Delle Pleuriti Suine in Sede Di Macellazione. La Griglia, S.P.E.S. (Slaughterhouse Pleuritis Evaluation System) O. Large Anim. Rev.
2007, 13, 161–165.
56. Merialdi, G.; Dottori, M.; Bonilauri, P.; Luppi, A.; Gozio, S.; Pozzi, P.; Spaggiari, B.; Martelli, P. Survey of Pleuritis and Pulmonary
Lesions in Pigs at Abattoir with a Focus on the Extent of the Condition and Herd Risk Factors. Vet. J. 2012, 193, 234–239. [CrossRef]
57. Robinson, N.A.; Loynachan, A.T. Cardiovascular and Hematopoietic Systems. In Diseases of Swine, 11th ed.; Zimmerman, J.J.,
Karriker, L.A., Ramirez, A., Schwartz, K.J., Stevenson, G.W., Zhang, J., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, USA, 2019;
pp. 221–233. ISBN 9781119350927. [CrossRef]
58. Thomson, J.R.; Friendship, R.M. Digestive system. In Diseases of Swine, 11th ed.; Zimmerman, J.J., Karriker, L.A., Ramirez,
A., Schwartz, K.J., Stevenson, G.W., Zhang, J., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, USA, 2019; pp. 234–263. ISBN
9781119350927. [CrossRef]
59. R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria,
2017; Available online: https://www.R-project.org/ (accessed on 20 November 2020).
60. Wickham, H. ggplot2: Elegant Graphics for Data Analysis; Springer: New York, NY, USA, 2016; Available online: https://ggplot2.ti
dyverse.org (accessed on 4 March 2021).
61. Hanbo Chen. VennDiagram: Generate High-Resolution Venn and Euler Plots. R Package Version 1.6.20. 2018. Available online:
https://CRAN.R-project.org/package=VennDiagram (accessed on 4 March 2021).
62. Marquer, P.; Rabade, T.; Forti, R. Pig farming in the European Union: Considerable variations from one member state to another.
Eurostat Statis Focus. 2014, 15, 1–13. Available online: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Archi
ve:Pig_farming_sector_-_statistical_portrait_2014 (accessed on 26 September 2021).
63. World Health Organization (WHO). Critically Important Antimicrobials for Human Medicine, 6th Revision 2018. World Health
Organization: Geneva, Switzerland, 2019. Available online: https://apps.who.int/iris/bitstream/handle/10665/312266/978924
1515528-eng.pdf?ua=1 (accessed on 1 April 2020).
64. European Medicines Agency. Categorisation of Antibiotics for Use in Animals for Prudent and Responsible Use. 2019. Available
online: https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-use-animalsprudent-responsible-use_
en.pdf (accessed on 2 February 2020).
65. Regulation (EU) 2019/4 of the European Parliament and of the Council of 11 December 2018 on the Manufacture, Placing
on the Market and Use of Medicated Feed, Amending Regulation (EC) No 183/2005 of the European Parliament and of
the Council and Repealing Council Directive 90/167/EEC (Text with EEA Relevance). 2019, pp. 1–23. Available online:
http://data.europa.eu/eli/reg/2019/4/oj (accessed on 2 July 2021).
66. Rodrigues da Costa, M. Evaluation of Current Feeding and Management Practices in Irish Pig Production and Future Strategies
for Improvement. Ph.D. Thesis, Universitat Autònoma de Barcelona, Barcelona, Spain, 2018. Available online: http://hdl.handle
.net/10803/666618 (accessed on 3 March 2021).
67. Stege, H.; Jensen, T.K.; Møller, K.; Bækbo, P.; Jorsal, S.E. Risk Factors for Intestinal Pathogens in Danish Finishing Pig Herds. Prev.
Vet. Med. 2001, 50, 153–164. [CrossRef]
68. Campbell, J.M.; Crenshaw, J.D.; Polo, J. The Biological Stress of Early Weaned Piglets. J Anim. Sci. Biotechnol. 2013, 4, 19.
[CrossRef]
Animals 2021, 11, 2828 22 of 23
69. Moeser, A.J.; Pohl, C.S.; Rajput, M. Weaning Stress and Gastrointestinal Barrier Development: Implications for Lifelong Gut
Health in Pigs. Anim. Nutr. 2017, 3, 313–321. [CrossRef] [PubMed]
70. Gebhardt, J.T.; Tokach, M.D.; Dritz, S.S.; DeRouchey, J.M.; Woodworth, J.C.; Goodband, R.D.; Henry, S.C. Postweaning Mortality
in Commercial Swine Production II: Review of Infectious Contributing Factors. Transl. Anim. Sci. 2020, 4, txaa052. [CrossRef]
[PubMed]
71. Gebhardt, J.T.; Tokach, M.D.; Dritz, S.S.; DeRouchey, J.M.; Woodworth, J.C.; Goodband, R.D.; Henry, S.C. Postweaning Mortality
in Commercial Swine Production. I: Review of Non-Infectious Contributing Factors. Transl. Anim. Sci. 2020, 4, txaa068. [CrossRef]
[PubMed]
72. Stevens, K.; Gilbert, J.; Strachan, W.; Robertson, J.; Johnston, A.; Pfeiffer, D. Characteristics of Commercial Pig Farms in Great
Britain and Their Use of Antimicrobials. Vet. Rec. 2007, 161, 45. [CrossRef] [PubMed]
73. Scali, F.; Santucci, G.; Maisano, A.M.; Giudici, F.; Guadagno, F.; Tonni, M.; Amicabile, A.; Formenti, N.; Giacomini, E.; Lazzaro, M.;
et al. The Use of Antimicrobials in Italian Heavy Pig Fattening Farms. Antibiotics 2020, 9, 892. [CrossRef]
74. Filippitzi, M.; Kruse, B.A.; Postma, M.; Sarrazin, S.; Maes, D.; Alban, L.; Nielsen, L.; Dewulf, J. Review of Transmission Routes of
24 Infectious Diseases Preventable by Biosecurity Measures and Comparison of the Implementation of These Measures in Pig
Herds in Six European Countries. Transbound. Emerg. Dis. 2018, 65, 381–398. [CrossRef]
75. Collineau, L.; Rojo-Gimeno, C.; Léger, A.; Backhans, A.; Loesken, S.; Nielsen, E.O.; Postma, M.; Emanuelson, U.; Beilage, E.;
Sjölund, M.; et al. Herd-Specific Interventions to Reduce Antimicrobial Usage in Pig Production without Jeopardising Technical
and Economic Performance. Prev. Vet. Med. 2017, 144, 167–178. [CrossRef] [PubMed]
76. Raasch, S.; Collineau, L.; Postma, M.; Backhans, A.; Sjölund, M.; Belloc, C.; Emanuelson, U.; Beilage, E.; Stärk, K.; Dewulf, J.; et al.
Effectiveness of Alternative Measures to Reduce Antimicrobial Usage in Pig Production in Four European Countries. Porc. Heal.
Manag. 2020, 6, 6. [CrossRef] [PubMed]
77. USDA. Swine 2012: Part I: Baseline Reference of Swine Health and Management in the United States, 2012. USDA-APHIS-VS,
CEAH, Fort Collins, CO. 2015; #663.0814. Available online: https://www.aphis.usda.gov/animal_health/nahms/swine/downl
oads/swine2012/Swine2012_dr_PartI.pdf (accessed on 16 March 2021).
78. Yaeger, M.J.; Alstine, W.G. Respiratory system. In Diseases of Swine, 11th ed.; Zimmerman, J.J., Karriker, L.A., Ramirez, A.,
Schwartz, K.J., Stevenson, G.W., Zhang, J., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, USA, 2019; pp. 393–407, ISBN
9781119350927. [CrossRef]
79. Gottschalk, M.; Segura, M. Streptococcosis. In Diseases of Swine, 11th ed.; Zimmerman, J.J., Karriker, L.A., Ramirez, A., Schwartz,
K.J., Stevenson, G.W., Zhang, J., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, USA, 2019; pp. 934–950, ISBN 9781119350927.
[CrossRef]
80. Aragon, V.; Segales, J.; Tucker, A.W. Glässer’s disease. In Diseases of Swine, 11th ed.; Zimmerman, J.J., Karriker, L.A., Ramirez,
A., Schwartz, K.J., Stevenson, G.W., Zhang, J., Eds.; John Wiley and Sons, Inc.: Hoboken, NJ, USA, 2019; pp. 844–853, ISBN
9781119350927. [CrossRef]
81. Steenhard, N.R.; Jungersen, G.; Kokotovic, B.; Beshah, E.; Dawson, H.D.; Urban, J.F.; Roepstorff, A.; Thamsborg, S.M. Ascaris suum
Infection Negatively Affects the Response to a Mycoplasma Hyopneumoniae Vaccination and Subsequent Challenge Infection in
Pigs. Vaccine 2009, 27, 5161–5169. [CrossRef] [PubMed]
82. Callens, B.; Persoons, D.; Maes, D.; Laanen, M.; Postma, M.; Boyen, F.; Haesebrouck, F.; Butaye, P.; Catry, B.; Dewulf, J. Prophylactic
and Metaphylactic Antimicrobial Use in Belgian Fattening Pig Herds. Prev. Vet. Med. 2012, 106, 53–62. [CrossRef] [PubMed]
83. Cameron-Veas, K.; Solà-Ginés, M.; Moreno, M.A.; Fraile, L.; Migura-Garcia, L. Impact of the Use of β-Lactam Antimicrobials on
the Emergence of Escherichia Coli Isolates Resistant to Cephalosporins under Standard Pig-Rearing Conditions. Appl. Environ.
Microbiol. 2015, 81, 1782–1787. [CrossRef]
84. Kruse, A.B.; Knegt, L.V.; de Nielsen, L.R.; Alban, L. No Clear Effect of Initiating Vaccination against Common Endemic Infections
on the Amounts of Prescribed Antimicrobials for Danish Weaner and Finishing Pigs during 2007–2013. Front. Vet. Sci. 2017, 3,
120. [CrossRef]
85. Holt, H.R.; Alarcon, P.; Velasova, M.; Pfeiffer, D.U.; Wieland, B. BPEX Pig Health Scheme: A Useful Monitoring System for
Respiratory Disease Control in Pig Farms? BMC Vet. Res. 2011, 7, 82. [CrossRef]
86. Opriessnig, T.; Giménez-Lirola, L.; Halbur, P. Polymicrobial Respiratory Disease in Pigs. Anim. Health Res. Rev. 2011, 12, 133–148.
[CrossRef]
87. Díaz, J.A.C.; Fitzgerald, R.M.; Shalloo, L.; da Costa, M.R.; Niemi, J.; Leonard, F.C.; Kyriazakis, I.; Manzanilla, E.G. Financial
Analysis of Herd Status and Vaccination Practices for Porcine Reproductive and Respiratory Syndrome Virus, Swine Influenza
Virus, and Mycoplasma Hyopneumoniae in Farrow-to-Finish Pig Farms Using a Bio-Economic Simulation Model. Front. Vet. Sci.
2020, 7, 556674. [CrossRef]
88. Regulation (EU). 2019/6 of the European Parliament and of the Council of 11 December 2018 on Veterinary Medicinal Products
and Repealing Directive 2001/82/EC (Text with EEA Relevance). 2019, pp. 43–167. Available online: http://data.europa.eu/eli
/reg/2019/6/oj (accessed on 4 April 2020).
89. UK-VARSS. UK Veterinary Antibiotic Resistance and Sales Surveillance Report (UK-VARSS 2019). Veterinary Medicines Direc-
torate. 2020. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/950126/UK-VARSS_2019_Report__2020-TPaccessible.pdf (accessed on 20 December 2020).
90. Aarestrup, F. Sustainable Farming: Get Pigs off Antibiotics. Nature 2012, 486, 465–466. [CrossRef]
Animals 2021, 11, 2828 23 of 23
91. Speksnijder, D.; Mevius, D.; Bruschke, C.; Wagenaar, J. Reduction of Veterinary Antimicrobial Use in the Netherlands. The Dutch
Success Model. Zoonoses Public Health 2015, 62, 79–87. [CrossRef]
92. Rojo-Gimeno, C.; Postma, M.; Dewulf, J.; Hogeveen, H.; Lauwers, L.; Wauters, E. Farm-Economic Analysis of Reducing
Antimicrobial Use Whilst Adopting Improved Management Strategies on Farrow-to-Finish Pig Farms. Prev. Vet. Med. 2016, 129,
74–87. [CrossRef]
93. Postma, M.; Vanderhaeghen, W.; Sarrazin, S.; Maes, D.; Dewulf, J. Reducing Antimicrobial Usage in Pig Production without
Jeopardizing Production Parameters. Zoonoses Public Health 2017, 64, 63–74. [CrossRef] [PubMed]
94. Diana, A.; Boyle, L.A.; Leonard, F.C.; Carroll, C.; Sheehan, E.; Murphy, D.; Manzanilla, E.G. Removing Prophylactic Antibiotics
from Pig Feed: How Does It Affect Their Performance and Health? BMC Vet. Res. 2019, 15, 67. [CrossRef] [PubMed]
95. European Commission. Commission Implementing Decision of 26.6.2017 Concerning, in the Framework of Article 35 of
Directive 2001/82/EC of the European Parliament and of the Council, the Marketing Authorisations for Veterinary Medicinal
Products Containing “Zinc Oxide” to be Administered Orally to Food Producing Species. 2017. Available online: https:
//ec.europa.eu/health/documents/community-register/2017/20170626136754/dec_136754_en.pdf (accessed on 16 September
2021).
96. Nielsen, C.; Kongsted, H.; Sørensen, J.; Krogh, M. Antibiotic and Medical Zinc Oxide Usage in Danish Conventional and
Welfare-Label Pig Herds in 2016–2018. Prev Vet Med 2021, 189, 105283. [CrossRef] [PubMed]
97. Maes, D.; Deluyker, H.; Verdonck, M.; Kruif, A.; Ducatelle, R.; Castryck, F.; Miry, C.; Vrijens, B. Non-infectious Factors Associated
with Macroscopic and Microscopic Lung Lesions in Slaughter Pigs from Farrow-to-finish Herds. Vet. Rec. 2001, 148, 41–46.
[CrossRef] [PubMed]
98. Agostini, P.; Fahey, A.; Manzanilla, E.; O’Doherty, J.; de Blas, C.; Gasa, J. Management Factors Affecting Mortality, Feed Intake
and Feed Conversion Ratio of Grow-Finishing Pigs. Animal 2014, 8, 1312–1318. [CrossRef]
